Skip to main content
. Author manuscript; available in PMC: 2021 Apr 1.
Published in final edited form as: Nat Cancer. 2020 Sep 28;1(10):998–1009. doi: 10.1038/s43018-020-00115-2

Figure 6. SCD1 pharmacological inhibition decreases patient-derived xenograft (PDXs) engraftment in the CNS.

Figure 6

Human leukemia burden in PDXs. Cells from 4 different PDXs were injected intravenously into NSG mice. Xenografted mice were treated daily from day 7 with the SCD1 inhibitor SW203668 or vehicle (n=5 group) at 20 mg/kg. The total amounts of leukemic cells in CNS and BM of NSG mice at the time of sacrifice are plotted in the graphs (A-D). p=Student’s t-test.